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• Hormone therapy has been described as a risk 
factor for chronic pain conditions such as low back 
pain and temporomandibular disorders (TMD)1,2 
• Hormonal contraception (HC) may affect pain by 
altering the function of the endogenous opioid 
system3 and augmenting serotonin metabolism 4 
• HC has been shown to increase experimental heat 
and ischemic pain sensitivity in women with TMD 
and migraine headaches5 
• Women using HC also demonstrate decreased 
pressure pain and tactile thresholds of the 
temporalis and masseter muscles compared to 
healthy women not using HC6,7 
• An association between the use of HC and painful 
conditions such as migraine headaches and TMD2,5 
has been described in previous studies although the 
nature of this association remains unclear 
• This analysis sought to determine the relationship 
between HC use and painful symptoms (particularly 
headaches and orofacial pain) 
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Table 1. Association of HC use and pain complaints of 
various bodily regions Bibliography 
• OPPERA (Orofacial Pain: Prospective Evaluation 
and Risk Assessment) is a prospective cohort 
study designed to identify risk factors for the onset 
of TMD  
• 1,863 women who did not have TMD when 
examined at enrollment were recruited at 4 U.S. 
study sites from 2006-2008 
• Follow-up for up to five years was conducted using 
questionnaires completed every three months to 
evaluated the frequency and severity of the painful 
symptoms in the orofacial region 
• Follow-up questionnaires also asked about pain in 
other bodily regions and use of medications, 
including HC 
• Mixed effects regression models were used to 
evaluate the association between HC use and 
presence of orofacial pain symptoms in each 
three-month follow-up period 
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• There was a significant association between HC use 
and the presence of cheek and jaw pain (OR=1.5, 
95% CI=1.3,1.7) and headaches (OR=1.7, 95% 
CI=1.5,2.0) 
• When participants were asked to rate the intensity of 
their orofacial pain on a scale from 0 to 10, HC users 
reported greater pain intensity (mean 
difference=0.25, 95% CI=0.15,0.35) 
• There was also a statistically significant difference 
between HC users and non-users in the number of 
months with 5 or more days with orofacial pain 
(mean difference=0.03, 95% CI=0.01,0.04) 
• HC use was significantly associated with aches and 
pains lasting a day or longer in the face (OR=1.4, 
95% CI=1.0,1.8) and head (OR=1.3, 95% 
CI=1.1,1.6) 
• There was no significant association (at the p<0.05 
level) between HC use and aches and pains in other 
regions of the body 
• The results remained essentially unchanged after 
excluding women with pre-existing orofacial pain or 
severe menstrual pain or past HC use to treat pain 
• HC use was associated with the presence, severity, 
and duration of orofacial pain 
• No association was observed between HC use and 
pain in other bodily regions 
• After excluding women with pre-existing orofacial 
pain and severe menstrual pain, the association 
between HC use and orofacial pain remained, so it 
is unlikely that the association between HC use and 
orofacial pain can be explained by the likely use of 
HC by some women to treat dysmenorrhea and 
other painful conditions 
• The complex nature of the relationship between HC 
use and orofacial pain is a subject for future 
research 
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• Each three-month period had three outcome 
variables: 1) presence of orofacial pain and 
headache, 2) number of months with orofacial pain 
during the three-monthly period , and  3) aches and 
pains lasting a day or longer in each of 12 different 
bodily regions 
• HC use was modeled as a fixed effect, along with 
dummy variables for each study site, and a separate 
random effect was fitted for each participant 
• Standard linear mixed effects models were used for 
continuous outcome variables, and logistic 
generalized linear mixed models were used for 
binary outcome variables 
• Since HC can be used to treat menstrual pain and 
other types of pain, the analysis was repeated 
excluding women with pre-existing orofacial pain or 
severe menstrual pain and women who previously 
used HC to treat pain 
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Pain Region Event Total 
Odds 
Ratio 
95% Confidence 
Interval P-value 
Orofacial (Any) 6367 16088 1.51 [1.33, 1.72] <0.0001 
Headache 9553 15897 1.70 [1.47, 1.97] <0.0001 
Body Aches (Any) 6101 15803 1.11 [0.97, 1.27] 0.107 
   Head 1563 15803 1.34 [1.11, 1.62] 0.002 
   Face 585 15803 1.36 [1.0, 1.84] 0.045 
   Neck 1469 15803 1.16 [0.95, 1.43] 0.139 
   Hips 548 15803 0.81 [0.54, 1.22] 0.301 
   Hands 292 15803 1.20 [0.72, 1.98] 0.475 
   Abdomen 1024 15803 0.93 [0.73, 1.18] 0.522 
   Chest 264 15803 0.88 [0.51, 1.52] 0.639 
   Legs 1411 15803 1.04 [0.84, 1.28] 0.724 
   Back 2751 15803 1.02 [0.87, 1.20] 0.822 
   Shoulders 1452 15803 0.98 [0.79, 1.2] 0.839 
   Feet 627 15803 1.02 [0.75, 1.37] 0.922 
   Arms 627 15803 0.99 [0.72, 1.37] 0.973 
Table 2. Association of HC use and pain complaints of 
various body regions excluding women with pre-existing 
orofacial pain, severe menstrual pain, and past HC use to 
treat pain 
Pain Region Event Total 
Odds 
Ratio 
95% Confidence 
Interval P-value 
Orofacial (Any) 3256 9151 1.56 [1.32, 1.85] <0.0001 
Headache 4975 9034 1.73 [1.44, 2.09] <0.0001 
Body Aches (Any) 3012 8984 1.22 [1.03, 1.45] 0.020 
   Head 738 8928 1.45 [1.11, 1.90] 0.006 
   Face 288 8928 1.81 [1.16, 2.82] 0.008 
   Neck 686 8928 1.23 [0.92, 1.64] 0.153 
   Abdomen 419 8928 0.82 [0.58, 1.15] 0.238 
   Hips 237 8928 0.74 [0.42, 1.31] 0.295 
   Hands 147 8928 1.44 [0.68, 3.03] 0.335 
   Arms 290 8928 1.17 [0.80, 1.73] 0.410 
   Back 1308 8928 1.08 [0.86, 1.34] 0.512 
   Shoulders 665 8928 1.08 [0.81, 1.44] 0.593 
   Chest 127 8928 1.17 [0.55, 2.49] 0.680 
   Feet 285 8928 1.09 [0.72, 1.66] 0.680 
   Legs 640 8928 1.04 [0.78, 1.39] 0.773 
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